| Drug Name | ***0135 |
| Description |
A von Hippel–landau (VHL) E3 ligase-based proteolysis-targeting chimera consists of a potent Brd4 inhibitor conjugated to an antibody targeting c-type lectin domain family 12 member A (CLEC12) through a novel linker. The product showed significant antitumor activities without severe toxicity in preclinical studies. |
| Target | Brd4; CLEC12 |
| Drug Modality | PROTAC |
| Indication | Leukemia |
| Product Category | Signal Transduction Modulators |
| Mechanism of Action | Targeting CLEC12 expressed on tumor cells to induce Brd4 degradation |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |